akathisia/restlessness (26-29%) Parkinsonism (21-26%) Akathisia (20-21%) Headache (13-14%) Nausea (11-13%) Constipation (6-11%) Bipolar depression Extrapyramidal symptoms, all (10-19%) MDD (cariprazine and antidepressant therapy) Akathisia (7-23%) Extrapyramidal symptoms (5-18%) Insomnia (14-16%) Nausea (7-13%) Somnolence (5-11%) 1-10% Decreased appetite (>1%) Schizophrenia Constipation (6-10%) Somnolence (5-10%) Nausea (5-8%) Abdominal pain (3-7%) Restlessness (4-6%) Anxiety (3-6%) Toothache (3-6%) Hypertension (2-7%) Dyspepsia (4-5%) Vomiting (4-5%) Dizziness (3-5%) Agitation (3-5%) Diarrhea (1-5%) Pain in extremity (2-4%) Cough (1-4%) Tachycardia (2-3%) Increased weight (2-3%) Decreased appetite (1-3%) Dry mouth (1-3%) Fatigue (1-3%) Increased CPK (1-3%) Musculoskeletal stiffness (<3%) Back pain (1-3%) Dystonia (2%) Tachycardia (1-2%) Arthralgia (1-2%) Hepatic enzyme increased (1-2%) Nasopharyngitis (1-2%) Urinary tract infections (1-2%) Rash (1-2%) Bipolar mania Vomiting (8-10%) Insomnia (8-9%) Dyspepsia (7-9%) Somnolence (7-8%) Abdominal pain (6-8%) Restlessness (7%) Dizziness (6-7%) Diarrhea (5-6%) Hypertension (4-5%) Fatigue (4-5%) Dystonia (3-5%) Blurred vision (4%) Decreased appetite (3-4%) Toothache (3-4%) Pain in extremity (2-4%) Pyrexia (1-4%) Weight increased (2-3%) Increased CPK (2-3%) Dry mouth (2-3%) Oropharyngeal pain (1-3%) Back pain (1-3%) Hepatic enzymes increased (1-3%) Musculoskeletal stiffness (2%) Tachycardia (1-2%) Bipolar depression Insomnia (7-10%) Akathisia (6-10%) Nausea (7%) Somnolence (6-7%) Restlessness (2-7%) Extrapyramidal symptoms, excluding akathisia/restlessness (4-6%) Dizziness (3-4%) Fatigue (3-4%) Parkinsonism (3-4%) Increased appetite (3%) Increased weight (2%) Musculoskeletal stiffness (≤1%) MDD (cariprazine and antidepressant therapy) Fatigue (3-10%) Insomnia (9-10%) Restlessness (4-8%) Nausea (6-7%) Dizziness (4-5%) Dry mouth (3-5%) Constipation (2-5%) Increased appetite (2-5%) Blurred vision (1-4%) Nasopharyngitis (1-4%) Agitation (<3%) Weight increased (2-3%) Back pain (2-3%) Vomiting (1-3%) Anxiety (1-3%) Blurred vision (<2%) Palpitations (<2%) Hyperhidrosis (1-2%) Edema (1-2%) Myalgia (1-2%) <1% Gastroesophageal reflux disease (0.1-1%) Gastritis (0.1-1%) Suicide attempts (0.1-1%) Suicide ideation (0.1-1%) Hyponatremia (0.1-1%) Pollakiuria (0.1-1%) Hyperhidrosis (0.1-1%) Rhabdomyolysis (0.1%) Ischemic stroke (0.1%) Completed suicide (0.1%) Hepatitis (0.1%) Bipolar disorder Tardive dyskinesia (<1%) Dystonia (<1%) Postmarketing Reports Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome Black Box Warnings Increased mortality in elderly patients with dementia-related psychosis Elderly patients with dementia-related psychosis treatment with antipsychotic drugs are at an increased risk of death Not approved for treatment of patients with dementia-related psychosis Suicidal thoughts and behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors Safety and effectiveness of cariprazine has not been established in pediatric patients Contraindications Hypersensitivity to cariprazine Cautions Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis; a higher incidence of stroke and TIA, including fatal stroke, was also observed (see Black Box Warnings) Hypersensitivity reactions reported ranging fom rash, pruritus, urticaria, and events suggestive of angioedema (eg, swollen, tongue, lip swelling, face edema, pharyngeal edema, facial swelling) Neuroleptic malignant syndrome reported; monitor for hyperpyrexia, muscle rigidity, delirium, and autonomic instability; other signs include increased CPK, myoglobinuria (rhabdomyolysis), and acute renal failure; if NMS is suspected, immediately discontinue treatment Tardive dyskinesia, a potentially irreversible, involuntary, dyskinetic movement syndrome, may develop in patients treated with antipsychotics Adverse effects may first appear several weeks after initiating treatment, as drug and metabolite levels accumulate; monitor for extrapyramidal symptoms or akathisia Leukopenia and neutropenia reported; agranulocytosis (including fatal cases) reported with other atypical antipsychotics; discontinue cariprazine in patients with absolute neutrophil count <1000/mm³ and follow WBC until recovery May cause orthostatic hypotension and syncope; caution in patients vulnerable to hypotension (eg, elderly, dehydration, hypovolemia, concomitant antihypertensive drugs, cardiovascular or cerebrovascular disease) May cause seizures; risk is greatest with history of seizures or conditions that lower seizure threshold Body temperature dysregulation reported; may disrupt ability to reduce core body temperature; caution with strenuous exercise, exposure to extreme heat, dehydration, and coadministration with anticholinergic medications Esophageal dysmotility and aspiration reported with antipsychotic drug use May cause somnolence with potential to impair judgment or thinking; may cause postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries; for patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy Drug interactions overview Coadministration with a strong CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of cariprazine alone (see Dosage Modifications) Effect of CYP3A4 inducers on the exposure of cariprazine has not been evaluated, and net effect is unclear Metabolic changes Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, reported; assess fasting plasma glucose before or soon after initiation of antipsychotic medication, and monitor periodically Lipids alteration has occurred; obtain a fasting lipid profile at baseline and monitor periodically during treatment before or soon after initiation of antipsychotic medication Weight gain observed; monitor weight at baseline and frequently thereafter Suicidal thoughts or behaviors Pooled analyses of placebo-controlled trials of antidepressive drugs showed an increased risk of suicidal thoughts or behavior in patients aged ≤24 yr taking these drugs for any indication; monitor for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior Inform patients, their caregivers, and families of the increase the risk of suicidal thoughts and behavior; advise to be alert for the emergence or worsening of signs and symptoms Pregnancy Neonates exposed to antipsychotic drugs during third trimester of pregnancy are at risk for extrapyramidal symptoms or withdrawal symptoms after delivery; these complications vary in severity, with some being self-limited and others requiring ICU support and prolonged hospitalization Pregnancy exposure registry Report exposure during pregnancy to the National Pregnancy Registry for Atypical Antipsychotics 1-866-961-2388 OR, http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ Animal data Administration in pregnant rats during organogenesis at doses 0.2 to 3.5 times maximum recommended human dose caused fetal developmental toxicity at all doses, including reduced body weight, decreased male anogenital distance, and skeletal malformations of bent limb bones, scapula, and humerus Decreased postnatal survival, birth weight, and post-weaning body weight was also observed Lactation Unknown if distributed in human breast milk Present in rat milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal conditionPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Precise mechanism by which cariprazine works for schizophrenia or bipolar disorder is unknown Efficacy could be mediated through a combination of partial agonist activity at central dopamine (D2) and serotonin 5-HT1A receptors Forms 2 major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug Absorption Peak plasma time: 3-6 hr (cariprazine) Mean concentrations of DCAR and DDCAR are ~30% and 400%, respectively, of cariprazine concentrations by the end of 12-week treatment Distribution Protein bound: 91-97% (parent drug and metabolites) Metabolism Active metabolites: Desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR) are pharmacologically equipotent to cariprazine Extensively metabolized by CYP3A4 to DCAR and DDCAR Metabolized to a lesser extent by CYP2D6 to DCAR and DDCAR DDCAR is metabolized by CYP3A4 to a hydroxylated metabolite Elimination Half-life: 2-4 days (cariprazine); 1-3 weeks (DDCAR) Excretion, cariprazine 12.5 mg/day: Urine (21%); [1.2% unchanged] Instructions Take orally with or without food Discontinuation Decline in plasma concentrations of active drug and metabolites may not be immediately reflected in patients’ clinical symptoms Plasma concentration declines by 50% in ~1 week There are no systematically collected data to address switching patients from cariprazine to other antipsychotics or concomitant administration with other antipsychotics Storage Store at controlled room temperature (20-25ºC [68-77ºF]); excursions permitted between 15-30ºC (59-86ºF) Protect 3- and 4.5-mg capsules from light to prevent potential color fading No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print FormularyPatient DiscountsAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.Create Your List of PlansAdding plans allows you to:View the formulary and any restrictions for each plan.Manage and view all your plans together – even plans in different states.Compare formulary status to other drugs in the same class.Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions Tier Description 1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC NOT COVERED – Drugs that are not covered by the plan. Code Definition PA Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. QL Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. ST Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. OR Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. Plans Select State: Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Done Non-Medicare Plans Medicare Plans Done CLOSE Additional Offers CLOSE Email to Patient From: To: The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send CLOSE Email Forms to Patient From: To: The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send